BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 29499861)

  • 1. Risk management decisions in women with BRCA1 and BRCA2 mutations.
    Morgan R; Brown A; Hamman KJ; Sampson J; Naik A; Massimino K
    Am J Surg; 2018 May; 215(5):899-903. PubMed ID: 29499861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Decision-Making in Patients with Variant of Uncertain Significance in BRCA1 or BRCA2 Genes.
    Welsh JL; Hoskin TL; Day CN; Thomas AS; Cogswell JA; Couch FJ; Boughey JC
    Ann Surg Oncol; 2017 Oct; 24(10):3067-3072. PubMed ID: 28766224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Follow-up of carriers of BRCA1 and BRCA2 variants of unknown significance: variant reclassification and surgical decisions.
    Murray ML; Cerrato F; Bennett RL; Jarvik GP
    Genet Med; 2011 Dec; 13(12):998-1005. PubMed ID: 21811163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk-reducing surgery in BRCA1/BRCA2 mutation carriers: Are there factors associated with the choice?
    Manoukian S; Alfieri S; Bianchi E; Peissel B; Azzollini J; Borreani C
    Psychooncology; 2019 Sep; 28(9):1871-1878. PubMed ID: 31264307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences among a Portuguese cohort of BRCA pathogenic/likely pathogenic variants carriers choosing risk-reducing mastectomy or intensive breast surveillance.
    Torres S; Peleteiro B; Magalhães A; Garrido L; Costa S; Fougo JL
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7529-7538. PubMed ID: 36971799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Multigene Panel Testing on Surgical Decision Making in Breast Cancer Patients.
    Pederson HJ; Gopalakrishnan D; Noss R; Yanda C; Eng C; Grobmyer SR
    J Am Coll Surg; 2018 Apr; 226(4):560-565. PubMed ID: 29360614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
    Yamauchi H; Nakagawa C; Kobayashi M; Kobayashi Y; Mano T; Nakamura S; Arai M
    Breast Cancer; 2018 Mar; 25(2):141-150. PubMed ID: 29019095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines.
    So MK; Jeong TD; Lim W; Moon BI; Paik NS; Kim SC; Huh J
    Breast Cancer; 2019 Jul; 26(4):510-519. PubMed ID: 30725392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
    Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
    Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis.
    Metcalfe K; Huzarski T; Gronwald J; Kotsopoulos J; Kim R; Moller P; Pal T; Aeilts A; Eisen A; Karlan B; Bordeleau L; Tung N; Olopade O; Zakalik D; Singer CF; Foulkes W; Couch F; Neuhausen SL; Eng C; Sun P; Lubinski J; Narod SA;
    Br J Cancer; 2024 Feb; 130(2):269-274. PubMed ID: 38030749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast Cancer Risk Reduction Decisions of the BRCA-Positive Patient: An Observational Study at a Single Institution.
    Johns D; Agarwal J; Anderson L; Ying J; Kohlmann W
    J Womens Health (Larchmt); 2017 Jun; 26(6):702-706. PubMed ID: 27922795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk-reducing mastectomy in BRCA1/2 mutation carriers: factors influencing uptake and timing.
    van Driel CM; Eltahir Y; de Vries J; Jaspers JP; Oosterwijk JC; Mourits MJ; de Bock GH
    Maturitas; 2014 Feb; 77(2):180-4. PubMed ID: 24268650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and molecular characterization of the BRCA2 p.Asn3124Ile variant reveals substantial evidence for pathogenic significance.
    Surowy HM; Sutter C; Mittnacht M; Klaes R; Schaefer D; Evers C; Burgemeister AL; Goehringer C; Dikow N; Heil J; Golatta M; Schott S; Schneeweiss A; Bugert P; Sohn C; Bartram CR; Burwinkel B
    Breast Cancer Res Treat; 2014 Jun; 145(2):451-60. PubMed ID: 24728577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenicity evaluation of BRCA1 and BRCA2 unclassified variants identified in Portuguese breast/ovarian cancer families.
    Santos C; Peixoto A; Rocha P; Pinto P; Bizarro S; Pinheiro M; Pinto C; Henrique R; Teixeira MR
    J Mol Diagn; 2014 May; 16(3):324-34. PubMed ID: 24607278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgical Decision Making in the BRCA-Positive Population: Institutional Experience and Comparison with Recent Literature.
    Flippo-Morton T; Walsh K; Chambers K; Amacker-North L; White B; Sarantou T; Boselli DM; White RL
    Breast J; 2016; 22(1):35-44. PubMed ID: 26695813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer.
    Elsayegh N; Webster RD; Gutierrez Barrera AM; Lin H; Kuerer HM; Litton JK; Bedrosian I; Arun BK
    Cancer Med; 2018 Jun; 7(6):2718-2726. PubMed ID: 29733510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of germline test results on surgical decision making in women with invasive breast cancer.
    Vargason AB; Turner CE; Shriver CD; Ellsworth RE
    Cancer Genet; 2022 Aug; 266-267():81-85. PubMed ID: 35868102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variants of unknown significance in BRCA testing: impact on risk perception, worry, prevention and counseling.
    Richter S; Haroun I; Graham TC; Eisen A; Kiss A; Warner E
    Ann Oncol; 2013 Nov; 24 Suppl 8():viii69-viii74. PubMed ID: 24131974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative diagnosis of BRCA1/2 mutation impacts decision-making for risk-reducing mastectomy in breast cancer patients.
    Woo J; Gwak G; Park I; Bae BN; Lee SK; Chae BJ; Yu J; Lee JE; Kim SW; Nam SJ; Ryu JM
    Sci Rep; 2021 Jul; 11(1):14747. PubMed ID: 34285295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.